HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Memory Health Marketer Reminded About Brain Health Ad Claims Substantiation In NAD Review

Executive Summary

Michigan firm likely remembered burden for substantiating health as well as structure/function claims under FDA regulations for supplements after NAD reviewed its ad materials presented online, in videos and in news releases submitted by Vision Elements.

You may also be interested in...



MacuHealth Asserts ‘Rigorous Process’ In Research Supporting Claims, But No Bill Of Health From NAD

“MacuHealth believes challenged claims are thoroughly supported by the multitude of peer reviewed, published scientific studies” but NAD review on Vision Elements challenge finds firm’s research doesn’t support its claims.

FTC’s Monetary Relief Claims Dismissed In Prevagen Fraud Case; Supreme Court Decision Cited

The Federal Trade Commission’s claim for monetary relief against the Prevagen memory supplement marketer is dismissed by a New York district court judge, who cites a recent Supreme Court decision gutting the FTC’s long-favored mechanism for collecting monies under the FTC Act.

Prevagen ‘Improves Memory’ Claims Will Be Qualified Under Class Action Settlement

Quincy Bioscience doesn’t admit to “any liability or wrongdoing of any kind associated with the claims alleged” in settlement to complaint in federal court in Florida, but agrees to pay plaintiffs refunds of 30% of the MSRP for its supplements, up to $70 per individual claimant.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS153967

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel